Phathom Pharmaceuticals — Fact Sheet (August 2022)

2 slides from Phathom Pharmaceuticals's fact sheet, August 2022

Slide 1: Corporate Overview: About Us, Leadership and Clinical Trials
Phathom. PHARMACEUTICALS CORPORATE OVERVIEW August 2022 first gastric, anti-secretory agent con a new.class approved States, Europe, or Canada in over 30 years. Our development programs build upon a solid foundation of studies in over 8,000 patients around the world. Vonoprazan* is currently approve
Slide 2: Prevalence and Burden of Acid-Related Disorders
Phathom. PHARMACEUTICALS PREVALENCE AND BURDEN OF ACID-RELATED GERD (Gastroesophogeal Reflux Disease) GERD is a common, chronic, recurring condition caused by the exposure of gastric acid from the stomach to the esophagus. Over 65 million US patients are living with GERD and it is esti- mated that a